WSW, NY, November 26th, 2025, FinanceWire
When GLP-1 drugs like Ozempic and Wegovy hit the market, they didn’t just change how doctors treat obesity – they changed how investors think about medicine itself.
A single biologic began to displace a significant share of invasive weight-loss surgeries, created an entirely new category of care, and unleashed one of the fastest value-creation cycles in biotech history.
Now, in a very different corner of healthcare, MediWound (NASDAQ: MDWD) may be setting up a similar kind of shift. The company is using enzymatic therapeutics to reduce the need for surgical procedures in wound and burn care – turning a centuries-old surgical routine into a precise, biology-based treatment.
From Scalpel to Science
For decades, surgeons have had to physically cut away dead tissue – a process called debridement – to treat severe burns or chronic wounds. It’s painful, costly, and often imprecise. MediWound’s solution removes the scalpel from the equation.
Its technology uses enzymes derived from natural sources that selectively dissolve dead tissue while sparing healthy skin – a biochemical cleanup that happens without surgery.
The company’s FDA-approved product, NexoBrid, is already being used in more than 40 countries, including the U.S. and EU. It can prepare burn wounds for grafting within hours instead of days, reducing or sometimes avoiding the need for surgery. Hospitals report shorter stays and lower costs, and the therapy’s uptake is accelerating fast. MediWound has completed commissioning of its expanded facility, which will expand its production capacity six fold, and is expected to reach full operational readiness by year-end 2025 to keep up with global demand.
Next in line is EscharEx, the company’s late-stage program for chronic wounds such as diabetic and venous leg ulcers – a vast and costly area of unmet need. In a Phase 2 clinical study, EscharEx achieved 63 percent complete debridement in two weeks, compared with 0 percent in the comparator SANTYL group, and cut the median time to debridement to nine days (p < 0.05).
If its ongoing Phase 3 trial confirms those results, EscharEx could enter a U.S. market worth over $2.5 billion, with a recent market access study estimating potential peak sales of $831 million.
The GLP-1 Parallel – Biology Over Surgery
The comparison to GLP-1 drugs isn’t about metabolism – it’s about a structural revolution in medicine.
GLP-1s transformed metabolic care by proving that a single biologic approach could outperform surgery for many patients, delivering better outcomes at lower cost. MediWound’s platform applies that same principle to wound care:
- Replace surgical excision with a biologic mechanism
- Improve outcomes while reducing the total cost of care
- Scale globally once regulatory and manufacturing barriers fall
Both stories are about precision biology displacing invasive procedures – and both open entirely new commercial markets in the process.
Strategic Momentum and Scale
MediWound’s trajectory mirrors the early inflection point of the GLP-1 revolution – small at first, but increasingly validated by the biggest names in healthcare.
The company has partnered with leading wound-care players including Solventum (3M spinoff), Mölnlycke, Essity, MiMedx, and Kerecis (Coloplast). In 2024, it raised $25 million in a strategic investment led by Mölnlycke, followed by a €2.5 million grant from the European Innovation Council to advance EscharEx in the diabetic foot ulcer (DFU) program. In September 2025, MediWound strengthened its position further with a $30 million registered direct offering, extending its cash runway well beyond key clinical milestones.
As of September 30, 2025, MediWound reported $60 million in cash and equivalents and no debt. The global VALUE Phase 3 trial for EscharEx began enrolling in February 2025, with an interim analysis expected once two-thirds of patients complete treatment in mid-2026 and expects to initiate the DFU clinical trial in the second half of 2026.
Combined with steady revenue growth from NexoBrid – already stockpiled by the U.S. government through BARDA, the same agency that funds national defense medical countermeasures – the company appears well positioned to execute at scale.
A Shift Investors Are Starting to Notice
GLP-1 showed what happens when a biologic turns a niche treatment into a mass-market paradigm shift. The same underlying forces – biologic precision, lower costs, and global scalability – are now emerging in wound care.
MediWound’s enzymes don’t just treat wounds differently; they seem to reduce the need for surgery and, in many cases, provide a non-surgical alternative. History shows that when data, manufacturing, and partnerships align, these biological shifts tend to move fast – and the companies behind them rarely stay under the radar for long.
The Bottom Line
GLP-1 drugs redefined metabolic medicine by proving that a single biologic could reshape an entire industry. MediWound may be following that same playbook in a different arena – transforming wound care from a surgical craft into a precise, biology-driven science.
With an approved product in burns, a Phase 3 program in chronic wounds, expanding global capacity, and backing from industry leaders and public agencies, MediWound sits squarely at the intersection of biology, scalability, and unmet clinical need – the same ingredients that turned GLP-1s from niche science into a worldwide phenomenon.
For investors watching the next wave of biotech disruption, wound care may be more than a medical story – it could be the next GLP-1-style breakout
Recent News Highlights from MediWound
MediWound Reports Third Quarter 2025 Financial Results and Provides Corporate Update
MediWound Successfully Completes Commissioning of Expanded GMP Manufacturing Facility for NexoBrid
MediWound Announces $30 Million Registered Direct Offering of Ordinary Shares
Important Disclaimers and Disclosures: The author, Wall Street Wire, is a content and media technology platform that connects the market with under-the-radar companies. The platform operates a network of industry-focused media channels spanning finance, biopharma, cyber, AI, and additional sectors, delivering insights on both broader market developments and emerging or overlooked companies. The content above is a form of paid promotional content and advertising. Wall Street Wire receives cash compensation from MediWound Ltd. for promotional media services provided on an ongoing subscription basis. This content is for informational purposes only and does not constitute financial or investment advice. Wall Street Wire is not a broker-dealer or investment adviser. Full compensation details, information about the operator of Wall Street Wire, and the complete set of disclaimers and disclosures applicable to this content are available at: wallstwire.ai/disclosures. Market size figures or other estimates referenced in this article are quoted from publicly available sources; we do not independently verify or endorse them, and additional figures or estimates may exist. This article should not be considered an official communication of the issuer.